Full Press Release Details
SAN DIEGO,Nov. 4, 2025/PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:
21stAnnual Industry/Academia Precision Oncology & Radmed SymposiumNovember 5th, 2025 – La Jolla, California
Title:DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings SarcomaFormat:PresentationPresenters:Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, InhibrxDate:Wednesday, November 5th, 2025Time:4:45 PM Eastern Standard TimeLocation:The Alexandria at Torrey Pines, La Jolla, California
Connective Tissue Oncology Society (CTOS) 2025 Annual MeetingNovember 12th– 15th, 2025 – Boca Raton, Florida
Title:The Tetravalent Death Receptor 5 (DR5) Agonist ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results from the Randomized, Registrational, Phase 2 ChonDRAgon StudyLead Author:Robin L. Jones, MD – Medical Oncology, The Royal Marsden and Institute of Cancer ResearchFormat:PresentationDate:Friday, November 14th, 2025Time:8:30 AM – 10:00 AM Eastern Standard TimeLocation:The Boca Raton, Boca Raton, Florida
Society for NeuroOncology (SNO) 2025 Annual MeetingNovember 19th–23rd,2025 – Honolulu, Hawaii
Title:The Tetravalent Death Receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with TMZFormat:Poster PresentationDate:Saturday, November 22nd, 2025Time:4:45 pm – 6:00 PM Eastern Standard TimeLocation:Hawaii Convention Center, Honolulu, Hawaii; Kamehameha Exhibit Hall II & III
The presentation and poster will be accessible through a link on the investors' section of Inhibrx's website athttps://inhibrxbiosciences.investorroom.com/events-and-presentationsupon commencement of each event.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences' current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visitwww.inhibrx.com.
Investor and Media Contact:
Kelly Deck, CFO[email protected]858-795-4260
SOURCE Inhibrx Biosciences, Inc.